News headlines about Inogen (NASDAQ:INGN) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Inogen earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the medical technology company an impact score of 45.5660235751606 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

INGN has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $108.00 target price on shares of Inogen in a research note on Friday, September 1st. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reissued a “hold” rating and issued a $90.00 price objective on shares of Inogen in a research note on Tuesday, September 12th. Finally, Zacks Investment Research lowered shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $90.80.

Inogen (NASDAQ:INGN) traded up $3.16 during midday trading on Friday, hitting $101.17. 184,977 shares of the stock traded hands, compared to its average volume of 163,766. Inogen has a twelve month low of $53.53 and a twelve month high of $105.35. The stock has a market capitalization of $2.10 billion, a price-to-earnings ratio of 92.45, a price-to-earnings-growth ratio of 4.09 and a beta of 0.98.

Inogen (NASDAQ:INGN) last announced its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million during the quarter, compared to the consensus estimate of $59.99 million. During the same quarter in the previous year, the company posted $0.25 EPS. The firm’s revenue for the quarter was up 17.4% on a year-over-year basis. sell-side analysts expect that Inogen will post 1.2 earnings per share for the current fiscal year.

In other news, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the completion of the transaction, the director now owns 7,808 shares of the company’s stock, valued at approximately $715,759.36. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Heath Lukatch sold 2,500 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $97.44, for a total transaction of $243,600.00. Following the transaction, the director now directly owns 2,500 shares of the company’s stock, valued at approximately $243,600. The disclosure for this sale can be found here. Insiders sold a total of 73,667 shares of company stock valued at $7,041,641 in the last three months. 5.31% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-inogen-ingn-share-price/1678562.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.